CGEM | Cullinan Oncology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	12.50 - 13.52
52 Week Range	7.64 - 30.19
Beta	-0.21
Implied Volatility	96.86%
IV Rank	59.45%
Day's Volume	782,905
Average Volume	525,531
Shares Outstanding	58,227,600
Market Cap	732,503,208
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-01-08

Valuation
Profitability
Growth
Health
P/E Ratio	-4.43
Forward P/E Ratio	N/A
EPS	-2.84
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	85
Country	USA
Website	CGEM

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM's peers: ACET, AGIO, ALDX, ALVR, ALXO, ANNX, APLT, AURA, AUTL, AVTX, BCYC, BMEA, CCCC, CDXS, BOLT, DAWN, LYRA, SANA, OLMA, LIFE, ZNTL, IPSC, EWTX, MLYS, TALS, VOR, LYEL, GLUE, THRX, RVMD, CGTX, CNTA, COGT, CRDF, DSGN, DYN, ENTA, ERAS, EVAX, FDMT, FGEN, FHTX, CMPX, GHRS, GLTO, GNLX, HOWL, IGMS, IMAB, IMRX, IOBT, IVA, KALV, KNSA, KYMR, KZR, LGND, MDXG, MGNX, MIST, MRNS, MRSN, NUVL, NVCT, ORIC, PHAT, PRAX, PRTA, RCUS, RLAY, RLYB, RNA, ROIV, RYTM, SEER, SLDB, SLN, SMMT, SNDX, SRRK, TNGX, TPST, TRDA, TRVI, TSVT, TYRA, VALN, VERA, VIGL, VNDA, ZLAB, HLVX, PEPG, THRD, PMN, ERNA, NAMS, OABI, ELVN

*Chart delayed

Analyzing fundamentals for CGEM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see CGEM Fundamentals page.

Watching at CGEM technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CGEM Technicals page.